Cover Image
市場調查報告書

骨癌:開發中產品分析

Osteosarcoma - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 213052
出版日期 內容資訊 英文 287 Pages
訂單完成後即時交付
價格
Back to Top
骨癌:開發中產品分析 Osteosarcoma - Pipeline Review, H2 2017
出版日期: 2017年08月22日 內容資訊: 英文 287 Pages
簡介

骨癌是會破壞組織,造成骨骼脆弱的一種癌症,是骨癌中最常見的一種類型,會從形成新骨骼組織的幼若骨細胞開始惡化。症狀有疼痛、骨折、腫起、發紅、關節可動度有限等。危險因子有年齡,性別,家族病史及李-佛美尼症候群(Li-Fraumeni syndrome)等。骨癌的治療以手術、化療、放射線治療等組合治療最為常見。

本報告涵括全球骨癌治療藥的開發平台,提供您目前開發平台狀況和最新趨勢,藥物簡介,主要企業及他們開發中的產品評估等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

骨癌概要

治療藥的開發

  • 骨癌開發中產品:概要
  • 骨癌開發中產品:比較分析

骨癌:開發中的治療藥:各企業

骨癌:開發中的治療藥:大學·各研究機關

骨癌:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

骨癌:開發中的產品:各企業

骨癌:開發中的產品:各大學·研究機關

骨癌:治療藥的開發企業

  • Advaxis, Inc.
  • Amgen Inc.
  • AVEO Pharmaceuticals, Inc.
  • Bayer AG
  • Bellicum Pharmaceuticals, Inc.
  • Celldex Therapeutics, Inc.
  • CytRx Corporation
  • Eleison Pharmaceuticals LLC
  • Exelixis, Inc.
  • Isofol Medical AB
  • MediaPharma s.r.l.
  • Merck & Co., Inc.
  • Merrimack Pharmaceuticals, Inc.
  • Netris Pharma S.A.S.
  • Novartis AG
  • Oncolys BioPharma Inc
  • Pfizer Inc.
  • 鹽野義製藥
  • TEIJIN FIBERS製藥
  • United Therapeutics Corporation

骨癌:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

骨癌:暫停中的計劃

骨癌:開發終止的企劃

骨癌:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9655IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteosarcoma - Pipeline Review, H2 2017, provides an overview of the Osteosarcoma (Oncology) pipeline landscape.

Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone tissue. Symptoms include pain, bone fractures, swelling, redness and limitation of motion of joints. Risk factors include age, gender, family history and Li-Fraumeni syndrome. Treatment includes chemotherapy and surgery.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteosarcoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Osteosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 16, 4, 16 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 4, 2 and 4 molecules, respectively.

Osteosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteosarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Osteosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteosarcoma (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteosarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Osteosarcoma - Overview
    • Osteosarcoma - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Osteosarcoma - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Osteosarcoma - Companies Involved in Therapeutics Development
    • Advaxis Inc
    • Advenchen Laboratories LLC
    • Amgen Inc
    • AntiCancer Inc
    • Arrowhead Pharmaceuticals Inc
    • AVEO Pharmaceuticals Inc
    • Bayer AG
    • Bellicum Pharmaceuticals Inc
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Celldex Therapeutics Inc
    • Cellmid Ltd
    • CorMedix Inc
    • Daiichi Sankyo Company Ltd
    • Eisai Co Ltd
    • Eleison Pharmaceuticals LLC
    • Intezyne Technologies Inc
    • Ipsen SA
    • Isofol Medical AB
    • Johnson & Johnson
    • MacroGenics Inc
    • MD Biosciences GmbH
    • Merck & Co Inc
    • Merck KGaA
    • Novartis AG
    • Oncolys BioPharma Inc
    • Pfizer Inc
    • Teijin Pharma Ltd
  • Osteosarcoma - Drug Profiles
    • 12-B80 - Drug Profile
    • 3D-QM - Drug Profile
    • 3D-QMS - Drug Profile
    • A-1R - Drug Profile
    • ADXS-HER2 - Drug Profile
    • aldoxorubicin hydrochloride - Drug Profile
    • AM-7209 - Drug Profile
    • apatinib - Drug Profile
    • AT-69 - Drug Profile
    • AU-101 - Drug Profile
    • AV-203 - Drug Profile
    • avelumab - Drug Profile
    • axitinib - Drug Profile
    • BMTP-11 - Drug Profile
    • CAB-102 - Drug Profile
    • Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile
    • Cellular Immunotherapy to Target HER2 for Glioblastoma Multiforme and Osteosarcoma - Drug Profile
    • Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
    • Celyvir - Drug Profile
    • cisplatin SR - Drug Profile
    • daunorubicin hydrochloride - Drug Profile
    • dihydroartemisinin - Drug Profile
    • DS-5272 - Drug Profile
    • enoblituzumab - Drug Profile
    • everolimus - Drug Profile
    • glembatumumab vedotin - Drug Profile
    • ipilimumab + nivolumab - Drug Profile
    • irinotecan hydrochloride - Drug Profile
    • JNJ-7107 - Drug Profile
    • lenvatinib mesylate - Drug Profile
    • ligerin - Drug Profile
    • MD-401A - Drug Profile
    • Minnelide - Drug Profile
    • Modufolin - Drug Profile
    • Monoclonal Antibody for Osteosarcoma - Drug Profile
    • Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile
    • Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma - Drug Profile
    • OBP-702 - Drug Profile
    • Oligonucleotides to Inhibit Thymidylate Synthase and Dihydrofolate Reductase for Osteosarcoma and Colon Cancer - Drug Profile
    • pazopanib hydrochloride - Drug Profile
    • pembrolizumab - Drug Profile
    • radium Ra 223 dichloride - Drug Profile
    • RSF-101 - Drug Profile
    • SEN-461 - Drug Profile
    • sirolimus albumin-bound - Drug Profile
    • Small Molecules to Agonize Vitamin D3 Receptor for Osteosarcoma - Drug Profile
    • Small Molecules to Inhibit CaMKII for Osteosarcoma - Drug Profile
    • Small Molecules to Inhibit MDM2 for Osteosarcoma - Drug Profile
    • taurolidine - Drug Profile
    • Vaccine for Osteosarcoma - Drug Profile
    • VIMO-001 - Drug Profile
  • Osteosarcoma - Dormant Projects
  • Osteosarcoma - Discontinued Products
  • Osteosarcoma - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Osteosarcoma, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Osteosarcoma - Pipeline by Advaxis Inc, H2 2017
  • Osteosarcoma - Pipeline by Advenchen Laboratories LLC, H2 2017
  • Osteosarcoma - Pipeline by Amgen Inc, H2 2017
  • Osteosarcoma - Pipeline by AntiCancer Inc, H2 2017
  • Osteosarcoma - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2017
  • Osteosarcoma - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
  • Osteosarcoma - Pipeline by Bayer AG, H2 2017
  • Osteosarcoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2017
  • Osteosarcoma - Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • Osteosarcoma - Pipeline by Bristol-Myers Squibb Company, H2 2017
  • Osteosarcoma - Pipeline by Celldex Therapeutics Inc, H2 2017
  • Osteosarcoma - Pipeline by Cellmid Ltd, H2 2017
  • Osteosarcoma - Pipeline by CorMedix Inc, H2 2017
  • Osteosarcoma - Pipeline by Daiichi Sankyo Company Ltd, H2 2017
  • Osteosarcoma - Pipeline by Eisai Co Ltd, H2 2017
  • Osteosarcoma - Pipeline by Eleison Pharmaceuticals LLC, H2 2017
  • Osteosarcoma - Pipeline by Intezyne Technologies Inc, H2 2017
  • Osteosarcoma - Pipeline by Ipsen SA, H2 2017
  • Osteosarcoma - Pipeline by Isofol Medical AB, H2 2017
  • Osteosarcoma - Pipeline by Johnson & Johnson, H2 2017
  • Osteosarcoma - Pipeline by MacroGenics Inc, H2 2017
  • Osteosarcoma - Pipeline by MD Biosciences GmbH, H2 2017
  • Osteosarcoma - Pipeline by Merck & Co Inc, H2 2017
  • Osteosarcoma - Pipeline by Merck KGaA, H2 2017
  • Osteosarcoma - Pipeline by Novartis AG, H2 2017
  • Osteosarcoma - Pipeline by Oncolys BioPharma Inc, H2 2017
  • Osteosarcoma - Pipeline by Pfizer Inc, H2 2017
  • Osteosarcoma - Pipeline by Teijin Pharma Ltd, H2 2017
  • Osteosarcoma - Dormant Projects, H2 2017
  • Osteosarcoma - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Osteosarcoma - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Osteosarcoma, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top